anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND Morbihan disease, also known as Morbihan syndrome, is a rare medical condition characterized by chronic facial edema predominantly affecting the upper two-thirds of the face. Despite being recognized in medical literature for decades, its true prevalence and underlying pathophysiology remain poorly understood. Various hypotheses, including impaired lymphatic drainage, abnormal vascular permeability, immune dysregulation, and inflammatory reactions to demodex infestation, have been proposed to explain the etiology. CASE REPORT We present a case of a 61-year-old man with organized periocular edema of the upper third of the face, ultimately leading to Morbihan disease diagnosis. The patient underwent a midface lift, allowing for tissue retrieval for histopathological examination of the eyelid edematous skin, which revealed chronic inflammation, ectasia of small lymphatic vessels, and features of demodex intrafollicular localization. These findings were not specific, but consistent with the diagnostic hypothesis. The patient was referred to a rheumatologist for further evaluation and treatment. He did not respond well to systemic corticosteroids and immunosuppressive therapy. Rather, this resulted in extension of the edema to the upper eyelid. The patient opted not to undergo further treatment. CONCLUSIONS Morbihan disease is often misdiagnosed due to its rarity and overlapping clinical features with other facial conditions. Its management is challenging and can require a combination of medical and surgical interventions. Systemic corticosteroids, immunosuppressive agents, and topical treatments have had varying success. Surgical procedures, such as blepharoplasty or laser therapy, can be considered in severe cases. Early recognition and appropriate management are crucial to improving patient outcomes and quality of life.
Severe speech disorders lead to poor literacy, reduced academic attainment and negative psychosocial outcomes. As early as the 1950s, the familial nature of speech disorders was recognized, implying a genetic basis; but the molecular genetic basis remained unknown. In 2001, investigation of a large three generational family with severe speech disorder, known as childhood apraxia of speech (CAS), revealed the first causative gene; FOXP2. A long hiatus then followed for CAS candidate genes, but in the past three years, genetic analysis of cohorts ascertained for CAS have revealed over 30 causative genes. A total of 36 pathogenic variants have been identified from 122 cases across 3 cohorts in this nascent field. All genes identified have been in coding regions to date, with no apparent benefit at this stage for WGS over WES in identifying monogenic conditions associated with CAS. Hence current findings suggest a remarkable one in three children have a genetic variant that explains their CAS, with significant genetic heterogeneity emerging. Around half of the candidate genes identified are currently supported by medium (6 genes) to strong (9 genes) evidence supporting the association between the gene and CAS. Despite genetic heterogeneity; many implicated proteins functionally converge on pathways involved in chromatin modification or transcriptional regulation, opening the door to precision diagnosis and therapies. Most of the new candidate genes for CAS are associated with previously described neurodevelopmental conditions that include intellectual disability, autism and epilepsy; broadening the phenotypic spectrum to a distinctly milder presentation defined by primary speech disorder in the setting of normal intellect. Insights into the genetic bases of CAS, a severe, rare speech disorder, are yet to translate to understanding the heritability of more common, typically milder forms of speech or language impairment such as stuttering or phonological disorder. These disorders likely follow complex inheritance with polygenic contributions in many cases, rather than the monogenic patterns that underly one-third of patients with CAS. Clinical genetic testing for should now be implemented for individuals with CAS, given its high diagnostic rate, which parallels many other neurodevelopmental disorders where this testing is already standard of care. The shared mechanisms implicated by gene discovery for CAS highlight potential new targets for future precision therapies.
Adults (≥ 18 years of age) registered in the E-SUS or SIVEP-gripe RWD source data from August 16th, 2021 through April 21st, 2022, who received only one dose vaccination with CoronaVac and did not receive any other vaccine dose. Specifically, ≥14 days after receipt of the first vaccine dose and before the second dose of CoronaVac.
The present invention is about the RunCao soft capsule and the production method. The present invention is a capsule-typed compound for exogenous estrogen supplement and ovary nutrition. The health of the ovary can directly influence health and charm of the woman. The modern women are facing pressure from the work, life, family and feeling. Especially women above 30 years old bears much more pressure because the competition in the working place, therefore problems of endocrine dyscrasia, ovarian failure and reduction of estrogen secretion in women can cause all kinds of discomfort. The production comprises the toad oil with the weight portion ratio to the material as 10 to 30, soybean isoflavone as 5 to 15, the procyanidine as 3 to 10, the vitamin E as 2 to 10, the soybean oil as 50 to 80 and the adjuvant as 45 to 125, respectively. The product is applied in women for exogenous estrogen supplement and ovary nutrition. The product can help the ovary to recover health and activity by providing the ovary with sufficient nutrition.
The aims of the present study were twofold. Firstly, this study sought to examine the acute (1-d) effects of mid-morning milk consumption on subsequent metabolic, endocrine and appetite-related responses relative to an isoenergetic and isovolumetric serving of fruit-juice (part 1). Considering the putative mechanisms of milk consumption on appetite, feeding behavior and metabolism no studies are available that have explored the impact of daily milk or dairy food consumption on the above mentioned constructs in children and adolescents. This study therefore also aimed to compare the effect of daily (28-d) mid-morning milk or fruit-juice consumption on the above mentioned constructs (part 2).

Eleven adolescents participated in part 1 of this study and completed two trials (milk or fruit-juice mid-morning snack) in a randomized crossover design. For part 2, a parallel design with two intervention groups was employed. Participants were randomly allocated to groups, and received either a milk (n = 10) or an isocaloric and isovolumetric fruit-juice (n = 9) mid-morning snack for 28-d. On laboratory visits (for both part 1 and 2) participants remained at rest for 180 min. During this time, circulating concentrations of GLP-17-36, glucagon, insulin, leptin and blood glucose were determined. Measures of energy expenditure, substrate metabolism and subjective appetite were also collected. At 180 min, a homogenous ad libitum pasta meal was provided. For the remainder of the study day, subsequent energy intake was recorded utilizing a combined weighed self-reported food record and 24-h dietary recall technique.
This group will receive15 minutes of plantar vibration with frequency of 80 Hz, with 10 seconds of vibration and 5 seconds of rest with total time 15 min before the 50 minutes Otago exercise. The frequency of the exercise will be 3 times a week for 12 weeks.
Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. 9845429_ 1 (GHMatte) P47053.AU.5
The invention relates to a method for producing protoplasts of cassava or closely related species, which protoplasts are capable of regeneration into plants. The method comprises producing friable embryogenic callus from explants of cassava or closely related species and isolating protoplasts from said friable embryogenic callus. The invention also concerns protoplasts obtainable by said method. The invention further relates to a method for transforming such a protoplast of cassava or closely related species, and transformed protoplasts obtainable thereby. In addition, the invention concerns a method for regenerating plants from these protoplasts and a cassava plant or closely related species obtainable thereby. Starch isolated from tubers of such cassava plants have an increased amylopectin content. The starch and a method for isolating it from said plants also forms part of the invention.
Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
Sepsis-associated encephalopathy (SAE) is a critical neurological complication of sepsis and represents a crucial factor contributing to high mortality and adverse prognosis in septic patients. This study explored the contribution of NAT10-mediated messenger RNA (mRNA) acetylation in cognitive dysfunction associated with SAE, utilizing a cecal ligation and puncture (CLP)-induced SAE mouse model. Our findings demonstrate that CLP significantly upregulates NAT10 expression and mRNA acetylation in the excitatory neurons of the hippocampal dentate gyrus (DG). Notably, neuronal-specific Nat10 knockdown improved cognitive function in septic mice, highlighting its critical role in SAE. Proteomic analysis, RNA immunoprecipitation, and real-time qPCR identified GABABR1 as a key downstream target of NAT10. Nat10 deletion reduced GABABR1 expression, and subsequently weakened inhibitory postsynaptic currents in hippocampal DG neurons. Further analysis revealed that microglia activation and the release of inflammatory mediators lead to the increased NAT10 expression in neurons. Microglia depletion with PLX3397 effectively reduced NAT10 and GABABR1 expression in neurons, and ameliorated cognitive dysfunction induced by SAE. In summary, our findings revealed that after CLP, NAT10 in hippocampal DG neurons promotes GABABR1 expression through mRNA acetylation, leading to cognitive dysfunction.
<P>PROBLEM TO BE SOLVED: To minimize radiation of electromagnetic waves when making a radio communication between a terminal and an apparatus.  <P>SOLUTION: In this health control system, transmission and reception means 100 and 200 where a communication distance can be controlled to two or more stages (e.g. long distance communication of several tens meters and short distance communication of one meter and several tens centimeters) are provided respectively at the terminal 1000 and the apparatus 2000. When transmission is instructed by a transmission instruction means (transmission start button 120) provided at the terminal 1000, biological information obtained by a biological information obtaining means 130 provided at the terminal 1000 is transmitted through the long distance communication. When a transmission request signal sent through short distance communication by the apparatus 2000 is received by the terminal 1000, the biological information is transmitted from the terminal 1000 to the apparatus 2000 through the short distance communication.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
The combined hamartoma of the retina and the retinal pigment epithelium (CHR-RPE) is a rare but histologically benign tumor of which no clear consensus exists regarding its appropriate management. Most commonly CHR-RPE presents unilaterally in children as an elevated, pigmented lesion associated with vascular tortuosity and an epiretinal membrane (ERM). Patients may have decreased visual acuity (VA) in the affected eye, notably if the overlying ERM extends into the macula. For this reason, surgical intervention in the form of ERM removal has been pursued with notable success. Still, those who pursue observation cite the interwoven nature of the overlying glial membrane within the dysplastic retina, complicating surgery and accounting for variability in post-operative VA success. Given the rarity of the tumor coupled with the scarcity of data on its natural evolution, clinicians who pursue observation cannot know for sure whether withholding surgical management is predisposing their patients to worse visual outcomes as compared to those patients who undergo ERM peel as first-line therapy. This case report will discuss an infant with clinically diagnosed CHR-RPE whose lesion showed significant regression after 6 months of observation. This success story should cause ophthalmologists to reconsider the management options at their disposal when faced with a case of CHR-RPE, and to call for further research to better define the risks of observation over surgical intervention. [Ophthalmic Surg Lasers Imaging Retina 2024;55:471-473.].
The participant will benefit from three immersion sessions with the virtual reality headset, either individually or in a group session, accompanied by a team member trained in the use of the headset (psychomotrician, occupational therapist, doctor, psychologist, facilitator). At each session, the scale of observed emotions and the cybermalaise questionnaire will be completed (T1, T2, T3). At sessions 1 (T1) and 3 (T3), the investigator will administer the ECPAI behavior scale.
1,223,763. Chymotrypsin B. L'OPOCHIMIE. 29 Oct., 1968 [3 Nov., 1967], No. 51160/68. Heading C3H. In a process for obtaining chymotrypsin B by a fractionated precipitation of the proteins contained in a pulpy pancreas mixture followed by dissolution of the final cake in cold water, activation with trypsin and chromatographic purification, a first amount of ammonium sulphate is added to reach a degree of saturation of about 0À2, the mixture obtained is then filtered free of proteins of very high molecular weight and non-proteinaceous impurities, a second amount of ammonium sulphate is added to the filtrate to reach a degree of saturation comprised between 0À4 and 0À5 and the resulting mixture is filtered, giving a final cake the weight of which is approximately equal to 20% of that of the raw mixture of precipitable proteins contained in the aqueous extract before adding thereto said second amount of ammonium sulphate, said cake is redissolved in water, trypsin is added to the resulting solution in a quantity substantially equal to 1/40 of the weight of proteins contained in said solution, as determined from spectrophotometric readings, and the chymotrypsin B contained in the trypsinactivated solution is separated from other enzymes and proteins by a single chromatography. The cake may be dialysed to remove ammonium sulphate before the activation step.
[GB1223763A]
Oral medicinal preparation comprises (i) an iron-based phosphate adsorber, (ii) calcium salt, and/or (iii) an anion exchanger. The preparation is free of magnesium salts. An independent claim is also included for iron-based phosphate adsorber for oral administration, in combination with a calcium supplementation and/or with an anion exchanger, for medical use, in the absence of magnesium salts. ACTIVITY : Metabolic; Antidiarrheic. No biological data given. MECHANISM OF ACTION : None given.
The invention discloses an antibody capable of combining with human CCL1, which is characterized in that the antibody is an antibody of a) or b) or c), a) has a heavy chain variable region with an amino acid sequence shown as SEQ ID NO.1 and a light chain variable region with an amino acid sequence shown as SEQ ID NO. 2; b) The antibody has a heavy chain variable region with an amino acid sequence shown as SEQ ID NO.3 and a light chain variable region with an amino acid sequence shown as SEQ ID NO. 4; c) An antibody capable of binding to human CCL1 is obtained by substituting and/or deleting and/or adding one or more amino acid residues to the amino acid sequence shown in SEQ ID No.1 or SEQ ID No.2 or SEQ ID No.3 or SEQ ID No. 4. We have found that CCL1 can promote tumor cell proliferation, CCL1 can promote tumor progression in animals, and that CCL1 antibodies can inhibit CCL 1-induced cell proliferation and tumor progression by blocking CCL 1. CCL1 plays an important role in the progression of tumor development and is a potential target for tumor treatment.
The objectives of this double-blinded longitudinal study are to determine whether carnosine supplementation (1 g) for 6 months in subjects with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. In this pilot study there will be enrolled 120 subjects that will be divided into placebo (n=60) and carnosine groups (n=60). The distance covered on the 6-minute walk test (6-MWT) and the pain free walking capacity on the treadmill before and after the placebo or carnosine supplementation will be measured. Ankle branchial index (ABI), blood flow by magnetic resonance imaging (MRI) and laser doppler flowmetry (LDF) before and after the carnosine and placebo supplementation will be also measured. In addition, the carnosine will be measured by 1HMRS, global metabolomics and proteomics in the skeletal muscle will be performed, a comprehensive lipid and metabolic panels of blood will be performed, uptake of carnosine in red blood cells (RBCs) will be measured, and carnosine aldehyde conjugates in the urine before and after 6 months of carnosine and placebo supplementation will be evaluated. Following completion of the study, the subjects will be followed up for another 3 months and examine the durability of carnosine supplementation.
This study aimed to determine the fertility and growth traits, viability, and body measurements of the Romanov sheep under breeder conditions in the humid region of Turkey. The animal material of the research consisted of sheep imported from Ukraine in 2019. In the study, there are two farms with 31 and 44 ewes in the first year and three farms with 45, 34, and 32 ewes in the second year. The reproductive performances of 186 sheep and lambs in three different farms were examined, and nine rams, one ram per 20 sheep, were used for mating. Two-year (2020 and 2021) data on the reproductive performance of pure Romanov ewes, survivability in ewes and lambs, and development characteristics in lambs were used in the present study. The conceived rate (88.17%), fecundity at birth (1.42) and at weaning (1.29), litter size at birth (1.76) and weaning (1.56), single (50.98%), twin (41.83%), and triplet birth rate (6.54%), and abortion rate (6.71%) were determined for 2 years average. Birth and weaning weights of lambs were affected by sex and birth type (p < 0.01). The Romanov sheep and their lambs did not satisfy the breeder regarding reproductive performance and lamb development.
The investigators propose a pragmatic clinical trial to evaluate whether the IMPACT model will reduce hospital admissions and emergency room visits. All patients who meet the eligibility criteria will be randomized to be invited for assessment in IMPACT or be followed in usual care. Each FHT will generate a list of eligible participants drawn from their EMR. Participants will be randomly selected from this list and patients will be invited for an IMPACT assessment. Using data collected at each FHT by a trained chart abstractor on a monthly basis, all hospital admissions and emergency room visits will be counted. As well, all health service utilization for both intervention and control group will be collected. The investigators will compare the proportion of patients admitted to hospital or seen in the emergency room between the intervention and control group for the one year time period. For the secondary objectives of the study, patient and care givers in the intervention group will be asked to complete the Caregiver Strain Index (a standardized and validated instrument) both before the IMPACT intervention and up to 6 months later. The investigators will adapt an existing survey to measure health care professionals' experiences in providing care in an inter-professional team for seniors with complex chronic illness. The Dimensions of Teamwork Survey, will be administered at each FHT at the beginning of the study and at the end of the intervention period in order to assess team function and stability of team function. Lastly, interviews with patients, caregivers, and healthcare professionals will be conducted to explore satisfaction with the IMPACT experience and subsequent care as well as self-efficacy in managing their care. The interviews will be audio-recorded and professionally transcribed. Key themes emerging from the qualitative data will be identified. Preliminary findings will be subjected to a process of member checking/respondent validation to ensure accuracy of interpretation.
INTRODUCTION: Colorectal cancer (CRC) is the second most common and fatal cancer in China. circRNAs are different expressed between tumor and non-tumor tissues, and they are proved to be correlated with tumorigenesis and cancer progression.
OBJECTIVE: We aimed to explore the biological and molecular function of hsa_circ_0005939 in CRC.
METHODS: We collected and compared ten CRC tissues and four noncancerous tissues and performed circRNA sequencing. We investigated the hsa_circ_0005939 expression in fresh tissues from CRC and adjacent tissues by qPCR. Meanwhile, functional roles of hsa_circ_0005939 in CRC cells were explored by CCK-8, colony formation, wounding healing, cell apoptosis and western blot assays. RNA-FISH was used to confirm the cellular distribution of hsa_circ_0005939. Bioinformatic prediction and luciferase reporter assay were used to determine the mechanisms of hsa_circ_0005939.
RESULTS: Our results indicated that hsa_circ_0005939 was up-regulated in CRC tissues and cells. Up-regulation of hsa_circ_0005939 was associated with the occurrence and the number of lymph node metastasis of CRC. Hsa_circ_0005939 down-regulation inhibited cell proliferation, increased cell apoptosis and caused G2 phase arrest of CRC cells. Mechanistically, luciferase assay revealed that hsa_circ_0005939 acts as a molecular sponge for miR-4693-3p and then enhanced Ubiquitin Like With PHD And Ring Finger Domains 1 binding protein 1 like (UHRF1BP1L) expression.
CONCLUSION: Our findings indicated an oncogenic role of hsa_circ_0005939 in CRC, and it enhanced malignant phenotypes of CRC cells through miR-4693-3p/UHRF1BP1L axis. Our study may offer promising biomarkers and therapeutic targets for CRC.